VOLUNTIS: insider trades · France · AMF

About VOLUNTIS

Voluntis is a French company specialized in digital therapeutics, i.e. clinically validated software designed to support the management of patients living with chronic diseases. Over time, the group built its expertise around software platforms that combine patient data, therapeutic algorithms and clinical protocols, with an early focus on oncology and diabetes. The company was listed on Euronext Paris in May 2018 under ISIN code FR0004183960, before becoming a strategic acquisition target for U.S.-based Aptar in 2021. Aptar subsequently completed the purchase of a majority stake, representing about 64.6% of Voluntis’ share capital, and then launched a simplified tender offer followed by a squeeze-out. This marked a major milestone in Voluntis’ corporate history and confirmed the industrial value of its technology. Voluntis’ core business is the development of digital therapeutic solutions that help personalize patient care, improve treatment adherence and facilitate interaction between patients, healthcare professionals and pharmaceutical companies. Its products and services are primarily aimed at pharmaceutical groups, digital health players and, more broadly, healthcare ecosystems seeking validated digital monitoring tools. The company has notably worked on support programs in oncology, where optimized care pathways and remote monitoring are especially important. From a commercial standpoint, Voluntis positioned itself as one of the European pioneers in digital health, with the ability to deploy its solutions across multiple international markets. Historically, its footprint was organized between France and the United States, particularly around Paris and Cambridge, Massachusetts, allowing it to combine product innovation with access to the North American market. The company also formed partnerships with healthcare groups and medical interoperability specialists to strengthen integration of its solutions into care systems. A notable feature of Voluntis is that it entered a still-emerging niche at a very early stage: clinically validated digital therapeutics. Its trajectory reflects both the rise of digital medicine and the consolidation of the sector around players able to offer solutions that are regulatory-grade, technology-driven and focused on measurable clinical outcomes.